

## **2cureX announces issuance of patent on its ChemoCellomics® technology.**

**Copenhagen, Denmark, 21 October 2009:** 2cureX is pleased to announce that a broad patent protecting 2cureX's ChemoCellomics® technology has been issued (EP1759212). The patent describes how chemistry and cells can be integrated on any solid support. The technology has wide spread applications in multiple areas of life science.

Co-founder of 2cureX and inventor, Grith Hagel, says that "ChemoCellomics® now allows prospective screening of large collections of treatment regimens on cancer cells isolated from the individual patient. A pathophysiologically highly important aspect of this technology is that screening can be done shortly after removal of the tissue from the patient to ensure material quality that closely imitates the in-vivo situation".

"2cureX has established a highly dynamic network of academic and commercial partners to exploit the ChemoCellomics® technology within therapy of colorectal cancer. To support the subsequent commercialization it is very important that the core technology is effectively protected by this broad patent filing" said Ole Thastrup, CEO of 2cureX.

2cureX see a large potential for exploiting the now patent protected ChemoCellomics® technology outside the business focus of 2cureX.

### **Contacts:**

Ole Thastrup  
Chief Executive Officer

Tel: +45 45822036  
e-mail: ot@2curex.com

Timm Jessen  
Chief Business Officer

Tel: +49 (4315) 606 448  
e-mail: tj@2curex.com

### **About 2cureX**

- 2cureX is a Danish life science company that was spun-out of Carlsberg in 2006
- 2cureX develops a technology for individualised treatment of patients with solid cancers
- 2cureX is engaged in a comprehensive network of technical and clinical partners to exploit the ChemoCellomics® technology